Indeed, we observed that in colorectal cancer cell lines HCT15 (RAS-mutant) and RKO (BRAF-mutant), MEK and RAC inhibitors exhibit a synergistic suppressive activity (Figure 1). This evidence concerns the gene AKT1 and colorectal cancer.